Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDER Director Woodcock Plans Changes To Drug Reviews During OND Transition

Executive Summary

In podcast interview, US FDA’s Center for Drug Evaluation & Research Director Janet Woodcock discusses her plans the Office of New Drugs, including changes to the structure of the office to make reviews better managed and more uniform across divisions. Woodcock says she expects to stay in the interim OND role for most of 2017.


Related Content

US FDA Drug Office Reform: 'Everything' Is On The Table
'Just Say It!' – New Streamlined Guidance Format Coming, FDA's Woodcock Says
Gottlieb Promotes 'Team' Work For Product Reviews
Alzheimer's Guidance Coming From US FDA, Part Of Broader OND Reform
Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews
Woodcock Wants Rapid Regulatory Policy Development
Autism Feedback To FDA: Focus On Communication, Redefine 'Irritability'
A Hiring Freeze By A Different Name: OMB Wants Agency 'Workforce Reduction' Plans
Gottlieb's FDA: Specialized Groups Could Create Review Consistency, Speed
Jenkins' Retirement From US FDA Was Several Years In The Making





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts